Researchers reported a targeted lipid nanoparticle (LNP) strategy that enables in vivo gene editing of human blood stem cells without viral vectors. Published in Nature Biomedical Engineering, the work describes an approach designed to deliver editing machinery directly to hematopoietic stem cells in the body. The preclinical implications center on a long-standing bottleneck in gene editing—achieving efficient delivery while minimizing off-target exposure and delivery-related toxicity. Non-viral systems can also offer manufacturing and scalability advantages compared with viral platforms. If the method translates, it could expand options for therapies targeting blood disorders and broaden the delivery toolkit for ex vivo and in vivo gene-editing programs.